Eric Swayze Sells 1,194 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total transaction of $45,276.48. Following the completion of the transaction, the executive vice president now owns 33,713 shares of the company’s stock, valued at $1,278,396.96. This trade represents a 3.42 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Eric Swayze also recently made the following trade(s):

• On Wednesday, October 16th, Eric Swayze sold 53 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $38.31, for a total value of $2,030.43.

Ionis Pharmaceuticals Trading Down 7.8 %

NASDAQ IONS opened at $34.34 on Friday. The firm has a market capitalization of $5.42 billion, a PE ratio of -14.07 and a beta of 0.39. The business’s 50-day moving average price is $39.62 and its two-hundred day moving average price is $42.75. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86. Ionis Pharmaceuticals, Inc. has a 12 month low of $34.24 and a 12 month high of $54.44.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Guggenheim lowered their price target on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. Piper Sandler cut their price target on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a research note on Thursday. BMO Capital Markets cut shares of Ionis Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $67.00 to $60.00 in a research report on Friday, August 2nd. Wells Fargo & Company decreased their price objective on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th. Finally, Barclays lifted their price objective on shares of Ionis Pharmaceuticals from $45.00 to $51.00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.65.

Institutional Trading of Ionis Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its position in shares of Ionis Pharmaceuticals by 83.9% during the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after buying an additional 303 shares during the period. nVerses Capital LLC bought a new position in shares of Ionis Pharmaceuticals in the 2nd quarter worth about $29,000. Itau Unibanco Holding S.A. acquired a new position in shares of Ionis Pharmaceuticals in the 2nd quarter valued at about $37,000. Mather Group LLC. boosted its position in shares of Ionis Pharmaceuticals by 35.8% during the 2nd quarter. Mather Group LLC. now owns 911 shares of the company’s stock valued at $39,000 after purchasing an additional 240 shares in the last quarter. Finally, Capital Performance Advisors LLP acquired a new stake in Ionis Pharmaceuticals during the third quarter worth approximately $40,000. 93.86% of the stock is currently owned by institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.